Kornimate/medical-research-clean huggingface dataset:
ventilatory effects of thrive during ebus

Conditions: Hypercapnia; Sedation Complication; High Flow Nasal Cannula

Summary: high flow nasal cannula (hfnc) is used in interventional procedures to prevent hypoxia during sedation. in patients with a patent airway, hfnc reduces dead space ventilation as well. it is unknown if dead space ventilation is also reduced by hfnc in an endobroncheal ultrasound procedure, in which the airway is partially blocked by the endoscope. especially in patients with chronic obstructive pulmonary disease (copd) the partial blocking of the airway may reduce ventilation. if hfnc is able to reduce dead space during an ebus-procedure, it may facilitate co2 clearance, which may lead to a reduction in work of breathing. this study aims to investigate if hfnc reduces dead space ventilation in patients undergoing an ebus-procedure and if this is flow-dependent. a randomized, double-blinded, cross-over study is designed.


Eligibility criteria:
inclusion criteria: * adult patients with copd gold classification 3 or 4 * scheduled ebus with sedation exclusion criteria: * known neurodegenerative diseases, such as amyotrophic lateral sclerosis, dementia, multiple sclerosis or guillain-barré. * allergy or intolerance for propofol or esketamine * severe pulmonary hypertension (papsyst \> 60 mmhg) * pregnancy * upper airway obstruction, such as subglottic stenosis or obstructing tumors.

Keywords: high flow nasal cannula sedation dead space ventilation
pain neuroscience education in students

Conditions: Chronic Pain; Educational Problems

Summary: this study was designed to evaluate the effect of a 70-minute pain neuroscience education (pne) session on physiotherapy students' knowledge of pain and their beliefs and attitudes about the treatment of patients with chronic pain.

to investigate the effect of a 70 minute pain neuroscience education session on physiotherapy students' knowledge of pain and their beliefs and attitudes about the treatment of patients with chronic pain. this study was a single-center, cross-sectional study on the pain knowledge of students in a four-year physiotherapy program and their beliefs and attitudes about patients with back pain.students were eligible to participate if they were enrolled at physiotherapy undergraduate program at kütahya health sciences university faculty of health sciences. individuals were excluded if they had previously received in depth-teaching on pain neuroscience. the study was completed with 156 students from different classes (first, second, and third year of the program) who agreed to participate in the study. all participants were informed about the study and signed informed consent forms. pain neurophysiology questionnaire and pain attitudes and beliefs scale for physiotherapists were used to assess pain knowladge and attitudes and beliefs. after recording their demographic information, the participants completed the neuroscience of pain questionnaire (npq) and pain attitudes and beliefs scale for physiotherapists (pabs-pt) at three time points: pre-pne, immediately post-pne, and 6 months after pne.

Eligibility criteria:
inclusion criteria: * participants who study in physiotherapy. * willing to participate exclusion criteria: * individuals in years 4 were excluded. * participants who received an in-depth session about pain previously.

Keywords: pain neuroscience education chronic pain physiotherapy students
effect of partial sleep deprivation on immunological system in peripheral blood

Conditions: Sleep Deprivation

Summary: sleep deprivation was found to affect many organs including the immune system and predisposing for various health consequences including diabetes hypertension infections and increase in neoplastic diseases. subjects will be evaluated for immune parameters in peripheral blood test following a regular nigh sleep and compared with a test performed following a night shift in which they slept less than 3 hours. each participant will serve as its own control.

overall study design and plan 1. subjects will be bled on the day of the experiment between 8and 9 am. 2. blood tubes will be tested for t cell markers, serum cytokines levels, and other immune parameters by western blots. 3. the first tube will be tested on the day of experiment. 4. the second tube will kept in the lab and will be tested 24 hours later. 5. the third tube will be kept in the pocket of the subject and be tested 24 hours later. 6. the fourth tube will be kept in the pocket of another subject and will be tested 24 hours later. 7. the subject will be tested again following 24 hours. 8. each subject will be tested twice following a regular 6-8 hours of sleep, and following an on call duty in which he slept less than 3 hours.

Eligibility criteria:
inclusion criteria: male and female ages 18-40 signed confirmed consent no evidence of chronic disease or chronic medications exclusion criteria: any type of acute infection or other acute illness

Keywords: t cell markers
comparison of 2 techniques of invasive mini surgery: coelioscopy mini-trocar and monotrocar in the adnexa no carcinologic surgery : forward-looking observational study.

Conditions: Gynecologic Surgical Procedures for Adnexa Surgery in Ovarian Disease

Summary: the advantages of the celioscopy mini--trocar and monotrocar technical are recognized. there is however no forward-looking or retrospective study comparing the microcomputed-celioscopy (use of microphone) - trocar of 3mm of diameter in access celioscopic pluri--trocar) in the celioscopy monotrocar ( a single intra-umbilical section) in gynecological surgery. the objective of this preliminary study is to compare both surgical care in terms of morbidity died operating, in adnexa surgeries.


Eligibility criteria:
inclusion criteria : * age \> 18 ans * oms = 2 * patient having an operating indication of adnexa surgery : unilateral or bilateral adnexectomy exclusion criteria: * contraindication to coelioscopy intervention
study comparing the mistent ses versus the xience ees stent

Conditions: Coronary Stenosis

Summary: the primary objective of this study is to compare the performance of mistent to that of xience in an all-comers patient population with symptomatic ischemic heart disease. the patients will be followed through 3 years for major clinical events.


Eligibility criteria:
inclusion criteria: all comers" patients: * male or female patients 18 years or older; * presence of one or more coronary artery stenoses of 50% or more in a native coronary artery or in a saphenous venous or arterial bypass conduit suitable for coronary stent implantation. * the vessel should have a reference vessel diameter ranging from 2.5 mm to 3.75 mm (no limitation on the number of treated lesions, vessels, or lesion length); all lesions of the patient must comply with the angiographic inclusion criteria. * the patient is judged to be capable of providing voluntary informed consent and has been fully informed of the nature of the study, is willing to comply with all study requirements and will provide written informed consent as approved by the ethics committee of the respective clinical site. exclusion criteria: * known pregnancy or breastfeeding at time of randomization; * known contraindication or hypersensitivity to sirolimus, everolimus, cobalt-chromium, or to medications such as aspirin, heparin, bivalirudin, and all of the following four medications: clopidogrel bisulfate, ticlopidine, prasugrel, ticagrelor; * concurrent medical condition with a life expectancy of less than 12 months. * the patient is unwilling/ not able to return for outpatient clinic at 1 month and 12 months follow-up. * currently participating in another trial and not yet at its primary endpoint.

Keywords: cad acs all comers pci
efficacy and safety study of short ragweed pollen sublingual-oral immunotherapy

Conditions: Allergy

Summary: the primary objective of this study is to demonstrate that slit administered pre-and co-seasonally is effective in reducing rhinoconjunctivitis symptoms during the entire short ragweed pollen season.


Eligibility criteria:
inclusion criteria: * allergic to ragweed exclusion criteria: * not allergic to ragweed * history of anaphylaxis * subject with chronic sinusitis, unstable angina, significant arrhythmia, uncontrolled hypertension, or other chronic or immunological disease * asthmatic subjects with fev1 or pef less than or equal to 80% predicted * subjects who have received experimental drug within 30 days prior to study admission * subjects who have received anit-ige medications in the last 12 months * subjects who have received ragweed immunotherapy in the last 3 years * subjects who are currently users of inhaled, intramuscular, or intravenous corticosteroids, tricyclic anti-depressants, beta blockers, and mao inhibitors * subjects refusing to sign epi-pen training form * females who are pregnant or breast feeding
mupirocin ointment to eliminate nasal carriage of staphylococcus aureus in hiv infection

Conditions: Staphylococcus Aureus; HIV Infections

Summary: staphylococcus aureus is a bacteria that causes serious, often life threatening infections including pneumonia, wound, and bloodstream infections. persons with aids are at high risk for s. aureus infections. they are also at high risk for nasal carriage of s. aureus. in fact, nasal carriage is a known risk factor for subsequent s. aureus infection. topical mupirocin, an antibiotic when applied to the anterior nares, is a safe, effective way to eliminate s. aureus colonization. some studies have shown that mupirocin can also decrease the risk of s. aureus infection, but many of those studies utilized historical controls and none were rigorously tested among aids patients over an extended period of time. the main purpose of this randomized, double-blinded, placebo controlled study is to determine if mupirocin can eliminate s. aureus nasal colonization in residents at psi (inpatient, drug rehabilitation facility for aids patients in the bronx.) psi residents currently have a high incidence of s. aureus nasal colonization and infection. nasal cultures followed by twice daily application of mupirocin vs. placebo for five days will be performed on a monthly basis for 8 months. the study will examine whether mupirocin decreases the incidence of s. aureus infections and prevents s. aureus nasal colonization. the study is important because it may show that mupirocin is an effective way to eliminate nasal colonization and prevent s. aureus infections in aids patients, among those at highest risk for serious s. aureus infection. hypothesis: monthly application of mupirocin will reduce nasal colonization with s.aureus

this was a randomized double-blinded placebo controlled trial. subjects were treated with intranasal mupirocin or placebo on a monthly basis and tested for nasal colonization a month after each treatment. this was performed up to 8 months.

Eligibility criteria:
inclusion criteria: * resident at project samaritan inc. (psi) exclusion criteria: * past hypersensitivity to mupirocin or glycerol * pregnancy * lactation * expected discharge from psi in the following month * treatment with intranasal mupirocin within the preceding two months

Keywords: mupirocin staphylococcus aureus colonization infection hiv
retrospective registry providing baseline data on the outcome of left atrial (la) or la appendage (laa) thrombus in patients with nonvalvular atrial fibrillation (af) or atrial flutter after standard of care (soc) anticoagulant therapy

Conditions: Atrial Fibrillation

Summary: thrombus outcome data will be collected retrospectively during 2011-2012 as a historical baseline of soc with oral vka (vitamin k antagonist(s) for the treatment of patients with nonvalvular af or atrial flutter documented with la/ laa thrombi on transesophag-eal echocardiography (tee). the study is a company-sponsored, global, multi-center, retrospective, non-interventional study. patients who suffered from hemodynamically stable nonvalvular af or atrial flutter and had a diagnosed la/ laa thrombus between january 1st, 2011 and december 31st, 2012 will be identified through screening and review of medical records and included in the registry. retrospective patient data will be collected from may 2nd, 2013 to may 2nd, 2014. the observation of each patient will cover the period from the diagnosis of an la/ laa thrombus until the end-of-treatment tee following the 3-12 week soc anticoagulation (ac) therapy. if no end-of-treatment tee has been performed during 3-12 weeks of ac therapy, the observational period will end at 12 weeks after diagnosis at the latest. if more than one tee was performed during treatment, the thrombus outcome will be collected from the last tee performed within 12 weeks of treatment start.


Eligibility criteria:
inclusion criteria: * men or women age ≥ 18 years at data recording * hemodynamically stable nonvalvular af or atrial flutter * documented la/ la thrombus on tee exclusion criteria: * valvular af ( esc 2012 definition) * history of cardiac thrombus confirmed on tee * intracardiac tumors, e.g. atrial myxoma * active endocarditis

Keywords: la/laa thrombus atrial fibrillation observation
feasibility tests for various prism configurations for visual field loss

Conditions: Hemianopia, Homonymous; Tunnel Vision; Visual Field Defect, Peripheral; Visual Field Constriction Bilateral; Visual Field Defect Homonymous Bilateral

Summary: the investigators will develop and test different configurations of high-power prisms to expand the field of vision of patients with visual field loss to assist them with obstacle detection when walking. the study will involve multiple visits (typically four) to schepens eye research institute for fitting and testing with the prism glasses. the overall objective is to determine best designs and fitting parameters for implementation in prism devices for future clinical trials.


Eligibility criteria:
inclusion criteria: * visual field loss, either peripheral field loss or hemianopic field loss * visual acuity of at least 20/50 in the better eye * in sufficiently good health to be able to complete sessions lasting 2-4 hours * able to independently walk short distances * able to give voluntary, informed consent * able to speak english exclusion criteria: * any physical or mental impairments, including cognitive dysfunction, balance problems or other deficits that could impair the ability to walk or use the prism spectacles * a history of seizures in the last 6 months * hemispatial neglect (subjects with hemianopic field loss only)

Keywords: visual field expansion prisms hemianopsia tunnel vision visual field loss
long-term follow-up of participants with cerebral adrenoleukodystrophy who were treated with lenti-d drug product

Conditions: Cerebral Adrenoleukodystrophy (CALD); Adrenoleukodystrophy (ALD); X-Linked Adrenoleukodystrophy (X-ALD)

Summary: this is a multi-center, long-term safety and efficacy follow-up study for participants with cerebral adrenoleukodystrophy (cald) who have received lenti-d drug product (eli-cel) in a parent clinical study (study ald-102 or study ald-104). after completing a parent clinical study (approximately 2 years), eligible participants will be followed for an additional 13 years for a total of 15 years post-drug product infusion. no investigational drug product will be administered in this study.


Eligibility criteria:
inclusion criteria: * provision of written informed consent for this study by the participant or participant's parent(s)/ legal guardian(s) and written informed assent by participant, if applicable * have received eli-cel in a parent clinical study exclusion criteria: * there are no exclusion criteria for this study

Keywords: adrenoleukodystrophy x-linked adrenoleukodystrophy hematopoietic stem cells
risk factors for carbapenem-resistant acinetobacter baumannii

Conditions: Acinetobacter Infections

Summary: it has been demonstrated that panresistant strains of acinetobacter species may be selected by antibiotic use \[4\], may be transmitted from person to person \[5\], and may be passed via environmental contamination \[6\]. surveillance for panresistant acinetobacter species should be a priority, given the lack of antibiotic options for the treatment of these infections. there are currently no data on the antibiotic susceptibility of acinetobacter species or on the rates of panresistant organisms. the elucidation of potential risk factors for resistant strains of acinetobacter is therefore an important task, and the use of alternative antibiotics should be considered in icus where these strains are endemic.

the elucidation of potential risk factors for resistant strains of acinetobacter is therefore an important task, and the use of alternative antibiotics should be considered in icus where these strains are endemic.he following information will be collected: age, sex, occupation, hospital location at the time of positive culture (er, medical ward, icu etc), date of positive culture, prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 30 days of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history. we will collect information retrospectively.

Eligibility criteria:
inclusion criteria: * positive cultures of carbapenem-resistant acinetobacter baumannii exclusion criteria: * not meeting inclusion criteria

Keywords: carbapenem-resistant acinetobacter baumannii positive culture positive culture for carbapenem-resistant acinetobacter
efficacy of cervical epidural injection and selective nerve root block

Conditions: Cervical Radiculopathy

Summary: cervical epidural steroid injections are an accepted treatment modality for radicular pain secondary to disc pathology. with the developing ultrasound technology, ultrasound guided cervical selective nerve root block has been successfully used in the treatment of cervical radiculopathy. we aimed to compare the efficacy of cervical interlaminar epidural injections and cervical selective nerve root block.


Eligibility criteria:
inclusion criteria: * cervical radicular pain based on history and physical exam * nrs pain score \> 3 exclusion criteria: * previous spine surgery * allergic reactions to drugs used in procedure * epidural steroid injection within past 2 years * radiculopathy not resulting from disc pathology (e.g. foraminal stenosis or tumor) * untreated coagulopathy
effects of 6 weeks totum-070 on lipid metabolism and cardiovascular health in individuals at increased cardio-metabolic risk

Conditions: Hypercholesterolemia; Cardiovascular Risk Factor; Dyslipidemias; Atherosclerosis; Cardio-metabolic Risk

Summary: this clinical study aims to assess the efficacy of 6 weeks 2.5g dose of totum-070, a mix of 5 plant extracts, on lipid metabolism and cardiovascular health in individuals at increased cardio-metabolic risk.


Eligibility criteria:
main inclusion criteria: * body mass index (bmi) between 18.5 and 35 kg/m² * moderate hypercholesterolemic subject without any clinical symptoms of hypercholesterolemia (xanthoma, recurrent chest and/or leg pain...) and not requiring immediate pharmacological lipid-lowering treatment according to the current recommendations (european society of cardiology /european atherosclerosis society, 2019) * fasting blood ldl cholesterol level (using friedewald estimation method) between 1.3 and 1.9 g/l * fasting blood triglycerides level ≤ 2.2 g/l main exclusion criteria: * suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal dysfunction or other metabolic disorder needing a dose adjustment in drug intervention according to the professional recommendations * suffering from an uncontrolled arterial hypertension (systolic blood pressure ≥ 160 mmhg and/or diastolic blood pressure ≥ 100 mmhg) * with a history of ischemic cardiovascular event * suffering from a severe chronic disease (e.g. cancer, hiv, renal failure, ongoing hepatic or biliary disorders, chronic inflammatory digestive disease, arthritis or other chronic respiratory trouble, etc.) or gastrointestinal disorders found to be inconsistent with the conduct of the study by the investigator (e.g. celiac disease) * fasting glucose plasma concentration \> 1.26 g/l

Keywords: moderate hypercholesterolemia nutrition healthcare plant extracts
early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen

Conditions: Prostate Cancer Metastatic

Summary: the purpose of this study is to allow patients similar to that evaluated in the tropic trial (nct00417079), and investigators access to cabazitaxel for the management of metastatic hormone refractory prostate cancer (mhrpc) in those patients who have progressed during or after docetaxel and to document the overall safety of cabazitaxel in these patients. please note that in each country, patient recruitment will end when cabazitaxel becomes commercially available.


Eligibility criteria:
inclusion criteria: * metastatic hormone refractory prostate cancer (mhrpc) previously treated with a docetaxel-containing regimen * disease progression during or after docetaxel-containing regimen for mhrpc * surgical or medical castration * eastern cooperative oncology group (ecog) performance status (ps): 0-2 * life-expectancy ≥3 months * adequate bone marrow, liver, and renal function: neutrophils\> 1500 /mm3; hemoglobin \> 10 g/dl; platelets \> 100 x109/l; bilirubin \< uln; sgot (ast) \< 1.5xuln; sgpt (alt) \< 1.5xuln; creatinine \< 1.5xuln. if creatinine 1.0 - 1.5 x uln, creatinine clearance will be calculated according to ckd-epi formula and patients with creatinine clearance \< 60 ml/min should be excluded. exclusion criteria: * prior radiotherapy to ≥ 40% of bone marrow * prior radionuclide therapy (samarium-153, strontium-89, p-32...) * prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment * active grade ≥2 peripheral neuropathy * active grade ≥2 stomatitis * active infection requiring systemic antibiotic or anti-fungal medication * active cancer (other than mhrpc) including prior malignancy from which the patient has been disease-free for ≤5 years (except superficial basal cell skin cancer) * known brain or leptomeningeal involvement * history of severe hypersensitivity reaction (≥grade 3) to docetaxel * history of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs * history of severe hypersensitivity reaction (≥grade 3) or intolerance to prednisone or prednisolone * uncontrolled severe illness or medical condition (including uncontrolled cardiac arrhythmias, angina pectoris, hypertension or diabetes mellitus). history of congestive heart failure (nyha iii or iv) or myocardial infarction within last 6 months is also not allowed. * concurrent or planned treatment with potent inhibitors or inducers of cytochrome p450 3a4/5 * participation in a clinical trial with any investigational drug * patient with reproductive potential not implementing accepted and effective method of contraception the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.